Efficacy of topiramate as add-on therapy in two different types of progressive myoclonic epilepsy.

The present article describes two unrelated cases of progressive myoclonic epilepsy (PME) of the Lafora's disease and Unverricht-Lundborg types who were treated with topiramate (TPM) as add-on therapy for their myoclonus. After the initiation of topiramate therapy both cases responded with marked decrease in myoclonic seizure frequency and improvement of quality of life. Topiramate appears to be a useful alternative agent in cases of PME and could be consider for adjunctive therapy.
AuthorsCaner Feyzi Demir, Hasan Hüseyin Ozdemir, Bülent Müngen
JournalActa medica (Hradec Králové) / Universitas Carolina, Facultas Medica Hradec Králové (Acta Medica (Hradec Kralove)) Vol. 56 Issue 1 Pg. 36-8 ( 2013) ISSN: 1211-4286 [Print] Czech Republic
PMID23909054 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Anticonvulsants
  • topiramate
  • Fructose
  • Anticonvulsants (therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Fructose (analogs & derivatives, therapeutic use)
  • Humans
  • Myoclonic Epilepsies, Progressive (drug therapy)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: